Payment overview · 2025
General Payments
$912.65
35 reported records · 16 companies
Healthcare provider profile · identity verified
Allison Dawn Waters, NP-C
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · GRAFTON, WV · NPI 1962874537
Verified facts
What the public records show
CMS Open Payments records show Allison Dawn Waters, NP-C received $912.65 in general payments during 2025 across 35 reported records.
Novo Nordisk Inc accounted for 20.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $186.55 | 20.4% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $170.77 | 18.7% | 4 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $140.45 | 15.4% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $90.22 | 9.9% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $44.04 | 4.8% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $43.00 | 4.7% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $39.61 | 4.3% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $38.93 | 4.3% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $36.53 | 4.0% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $30.01 | 3.3% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $24.25 | 2.7% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $23.40 | 2.6% | 1 | 2025 |
| Organogenesis Inc. | Unresolved — no canonical attribution shown | $17.16 | 1.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.79 | 1.5% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $12.50 | 1.4% | 1 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $1.44 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $912.65 | 35 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $167.48 | 3 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $140.45 | 4 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $122.22 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $90.22 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $48.55 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $44.04 | 3 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $43.00 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $39.61 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $38.93 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $36.53 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $30.01 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $25.45 | 3 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $24.25 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $23.40 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19.07 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $19.07 | 1 | 2025 |
Source payment records
|
|||||
| APLIGRAF Normalized: apligraf |
Device | Organogenesis Inc. | $17.16 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $16.33 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $13.79 | 1 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $12.50 | 1 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $1.44 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 78 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
78 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Tramadol Hcl | Tramadol Hcl | 173 | 42 |
| Pantoprazole Sodium | Pantoprazole Sodium | 154 | 53 |
| Atorvastatin Calcium | Atorvastatin Calcium | 149 | 51 |
| Levothyroxine Sodium | Levothyroxine Sodium | 145 | 43 |
| Losartan Potassium | Losartan Potassium | 136 | 44 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 133 | 41 |
| Metoprolol Succinate | Metoprolol Succinate | 128 | 36 |
| Omeprazole | Omeprazole | 126 | 41 |
| Lisinopril | Lisinopril | 124 | 41 |
| Amlodipine Besylate | Amlodipine Besylate | 113 | 36 |
| Gabapentin | Gabapentin | 105 | 31 |
| Montelukast Sodium | Montelukast Sodium | 95 | 30 |
| Methylprednisolone | Methylprednisolone | 81 | 61 |
| Ozempic | Semaglutide | 78 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 77 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 77 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 74 | 24 |
| Sertraline Hcl | Sertraline Hcl | 73 | 23 |
| Prednisone | Prednisone | 69 | 44 |
| Pravastatin Sodium | Pravastatin Sodium | 68 | 19 |
| Simvastatin | Simvastatin | 66 | 17 |
| Lorazepam | Lorazepam | 65 | 12 |
| Furosemide | Furosemide | 64 | 29 |
| Metformin Hcl | Metformin Hcl | 64 | 19 |
| Mounjaro | Tirzepatide | 63 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 62 | 22 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 61 | 50 |
| Famotidine | Famotidine | 59 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 52 | 23 |
| Trazodone Hcl | Trazodone Hcl | 52 | 16 |
| Alendronate Sodium | Alendronate Sodium | 50 | 15 |
| Alprazolam | Alprazolam | 50 | suppressed |
| Azithromycin | Azithromycin | 50 | 41 |
| Fenofibrate | Fenofibrate Nanocrystallized | 50 | 14 |
| Ibuprofen | Ibuprofen | 50 | 15 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 44 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 41 | 18 |
| Fluconazole | Fluconazole | 41 | 22 |
| Glipizide | Glipizide | 39 | 12 |
| Potassium Chloride | Potassium Chloride | 39 | 17 |
| Tresiba Flextouch U-200 | Insulin Degludec | 39 | suppressed |
| Chlorthalidone | Chlorthalidone | 38 | 14 |
| Meloxicam | Meloxicam | 38 | 14 |
| Tamsulosin Hcl | Tamsulosin Hcl | 38 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 36 | 11 |
| Methocarbamol | Methocarbamol | 36 | 11 |
| Metformin Hcl Er | Metformin Hcl | 35 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 35 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 33 | suppressed |
| Baclofen | Baclofen | 32 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 31 | suppressed |
| Topiramate | Topiramate | 29 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 28 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 28 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 28 | 23 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | 12 |
| Spironolactone | Spironolactone | 28 | 11 |
| Bupropion Xl | Bupropion Hcl | 27 | suppressed |
| Glipizide Er | Glipizide | 27 | suppressed |
| Amoxicillin | Amoxicillin | 26 | 21 |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Carvedilol | Carvedilol | 25 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 23 | suppressed |
| Ezetimibe | Ezetimibe | 23 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 23 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 22 | 11 |
| Jardiance | Empagliflozin | 22 | suppressed |
| Valsartan | Valsartan | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 21 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 21 | suppressed |
| Nitroglycerin | Nitroglycerin | 21 | suppressed |
| Nystatin | Nystatin | 21 | 13 |
| Allopurinol | Allopurinol | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 20 | 17 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 20 | suppressed |
| Cephalexin | Cephalexin | 19 | 13 |
| Lovastatin | Lovastatin | 19 | suppressed |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 16 |
| Glimepiride | Glimepiride | 18 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Repatha Sureclick | Evolocumab | 17 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Eliquis | Apixaban | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | 11 |
| Vascepa | Icosapent Ethyl | 16 | suppressed |
| Cefdinir | Cefdinir | 15 | 12 |
| Pregabalin | Pregabalin | 15 | suppressed |
| Celecoxib | Celecoxib | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $912.65 · 35 records | Novo Nordisk Inc | AIRSUPRA, APLIGRAF, AREXVY, CAPVAXIVE, Cologuard Collection Kit, EVENITY, GARDASIL 9, JARDIANCE, Kerendia, LEQVIO, LINZESS, LifeVest, NEXPLANON, Ohtuvayre, Ozempic, Rybelsus, TRELEGY ELLIPTA, VAXNEUVANCE, VOQUEZNA, Veozah, Wegovy | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error